Richard Hoppe
Academic Appointments
- Professor, Radiation Oncology - Radiation Therapy
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Radiation Therapy 875 Blake Wilbur Dr Clinic D Stanford, CA 94305-5847 Tel Work (650) 723-5510 Fax (650) 498-6922Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 723-5510Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Lymphoma
- Lymphoma
- Cutaneous Lymphoma
- Cutaneous Lymphoma - Radiation Oncology
- Hodgkin's Disease - Radiation Oncology
Administrative Appointments
- Chair, Stanford University School of Medicine - Radiation Oncology (2000 - present)
Professional Education
| Internship: | Northshore Medical Center-Salem Hospital OR (1972) |
| Board Certification: | Therapeutic Radiology, American Board of Radiology (1976) |
| Residency: | SUMC - Graduate Medical Education CA (1975) |
| Medical Education: | Cornell University Medical College NY (1971) |
Scientific Focus
Current Research Interests
Irradiation immunosuppression; total body irradiation;, psychosocial effects of cancer treatment; treatment of lymphoma;, mycosis fungoides.
Clinical Trials
- Allogeneic Transplantation Using TL1 & ATG for Older Patients with Hematologic Malignancies Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Recruiting
- Combined Blood Stem Cell and HLA Haplotype Match Living Donor Kidney Transplantation Recruiting
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Recruiting
- Phase I/II Low-dose (12 Gy) TSEBT+Vorinostat VS Low-dose TSEBT Monotherapy in Mycosis Fungoides Recruiting
Publications
- Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys. 2011; (4): e651-7
- Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. Int J Radiat Oncol Biol Phys. 2011; (5): 1374-9
- In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010; (28): 4324-32
- Cutaneous peripheral T-cell lymphoma associated with a proliferation of B cells. Am J Clin Pathol. 2009; (6): 810-9
- Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease. Oncol Res. 2009; (5-6): 287-92
Help
Trial Administration